REFERENCES
- Letscher-Bru V, Herbrecht R. Caspofungin: the first rep-resentative of a new antifungal class. J Antimicrob Chemother 2003; 51: 513–521.
- Keating GM, Jarvis B. Caspofungin. Drugs. 2001; 61: 1121–129.
- Cancer Therapy Evaluation Program. Common Toxicity Criteria. National Cancer Institute, Version 2.0, June 1, 1999. Available online at http://www.rtog.org/members/toxicity/ctc-manual6-1-99.pdf.
- Castagnola E, Machetti M, Cappelli B, et al. Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leu-kaemia or undergoing allogenic bone marrow transplant. Clin Microbiol Infect 2004; 10: 255–257.
- Franklin JA, McCormick J, Flynn PM. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J 2003; 22: 747–749.
- Cesaro S, Giacchino M, Locatelli F, et al. Safety and effi-cacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological Patients. BCM Infect Dis 2007; 7: 38, doi: 10.1186/1471-2334-7-28.
- Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23: 1093–1097.
- Cesaro S, Toffolutti T, Messina C, et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive my-cosis. Eur J Haematol 2004; 73: 50–55.
- Sallmann S, Heilmann A, Heinke F, et al. Capofungin ther-apy for Aspergillus lung infection in a boy with chronic granulo-matous disease. Pediatr Infect Dis J 2003; 22: 199–203.
- Wertz KK, Pretzlaff RK. Caspofungin in a pediatric patient with persistent candidemia. Pediatr Crit Care Med 2004; 5: 181–183.
- Natarajan G, G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M. Experience with caspofungin in the treatment of per-sistent fungemia in neonates. J Perinatol 2005; 25: 770–777.
- Groll AH, Attarbaschi A, Schuster FR, et al. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J Antimicrob Chemother 2006; 57: 527–35.
- Merlin E, Galambrun C, Ribaud P, et al. Efficacy and safety of caspofungin therapy in children with invasive fungal infections. Pediatr Infect Dis J 2006; 25: 1186–1188.
- Koo A, Sung L, Upton A, et al. Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children. Pediatr Infect Dis J 2007; 26: 854–856.